Recent venture-backed IPOs took a hit during Tuesday’s stock market slide, but at least five of the eight companies to go public in February managed to hold onto most of their post-IPO pop.
*Accuray (Nasdaq: ARAY) traded down $0.89 to $25.76 per share, well above its $18 offering price.
*Mellanox Technologies (Nasdaq: MLNX) traded down $0.93 to $20.88 per share, still above its $17 offering price.
*Optimer Pharmaceuticals (Nasdaq: OPTR) traded down $0.25 to $9.75 per share, still above its $7 offering price.
*Salary.com (Nasdaq: SLRY) traded down $0.40 to $11.85 per share, still above its $10.50 offering price.
*Switch & Data Facilites (Nasdaq: SDXC) traded down $1.11 to $18.61 per share, slightly above its $17 offering price.
*Extent (Nasdaq: XTNT) traded down $0.54 to $14.71 per share, still under its $16 offering price.
*Molecular Insight Pharmaceuticals (Nasdaq: MIPI) traded down $0.20 to $13 per share, still under its $14 offering price.
*Synta Pharmaceuticals (Nasdaq: SNTA) traded down $0.24 to $8.51 per share, still under its $10 offering price.